← Leaderboards
David R Andes
University Of Wisconsin Madison
$20,347,146
Attributed
$31,101,428
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$77,482,791 · 22
By mechanism
U19$60,879,258 · 13
R01$14,603,261 · 3
R21$832,474 · 2
K08$627,075 · 1
R25$540,540 · 1
P41$183 · 2
Top collaborators
- Cameron Robert Currie25 shared
- Aaron P Mitchell7 shared
- Martin D Burke5 shared
- Robert Andrew Cramer5 shared
- Timothy M Fan5 shared
- Linda E Hyman5 shared
- William J Steinbach5 shared
- Timothy S Bugni4 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- James L Keck$14,846,170
- Matthew E Lopper$117,986
- Jorge C Escalante$17,590,668
- Steven Gary Van Lanen$5,629,279
Others in their field
Top investigators on “Drug Resistance”
- Judith S. Currier · University Of California Los Angeles$207,752,958
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,910,108
- Ralph Parchment · Leidos Biomedical Research, Inc.$140,676,376
- Daniel R Kuritzkes · Brigham And Women'S Hospital$114,882,802
- Peter C Adamson · National Childhood Cancer Foundation$114,476,581
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,453,088
Research focus
Drug ResistanceBasePharmaceutical PreparationsInfectionResistanceAntimicrobialPathogenIn VitroEnvironmentIn VivoInnovationDrug DiscoverySourceEffective TherapyAntimicrobial DrugLeadDrug DevelopmentAntifungal AgentsAntimicrobial ResistanceFungusNatural ProductsPathway InteractionsAnimalsCommunities
Grant awards (88)
Vesicle-mediated drug resistance of Candida albicans biofilm$1,889,324
R01 · FY2025 · AI · contact PI
Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi$763,891
R01 · FY2025 · AI · contact PI
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training Course$108,108
R25 · FY2025 · AI
Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi$763,891
R01 · FY2024 · AI · contact PI
Vesicle-mediated drug resistance of Candida albicans biofilm$493,243
R01 · FY2024 · AI · contact PI
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training Course$108,108
R25 · FY2024 · AI
Novel antimicrobials targeting MDR pathogens from animal microbial symbionts$5,954,977
U19 · FY2023 · AI · contact PI
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses$1,295,717
U19 · FY2023 · AI · contact PI
Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi$710,036
R01 · FY2023 · AI · contact PI
In vivo Core$634,768
U19 · FY2023 · AI · contact PI
Admin Core$314,768
U19 · FY2023 · AI · contact PI
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training Course$108,108
R25 · FY2023 · AI
Novel antimicrobials targeting MDR pathogens from animal microbial symbionts$5,977,704
U19 · FY2022 · AI · contact PI
Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi$777,498
R01 · FY2022 · AI · contact PI
Admin Core$763,485
U19 · FY2022 · AI · contact PI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$702,349
R01 · FY2022 · AI
In vivo Core$514,964
U19 · FY2022 · AI · contact PI
Biofilm Induced Extracellular Vesicle Pathogenesis$378,741
R01 · FY2022 · AI · contact PI
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training Course$108,108
R25 · FY2022 · AI
Novel antimicrobials targeting MDR pathogens from animal microbial symbionts$5,982,443
U19 · FY2021 · AI · contact PI
In vivo Core$951,755
U19 · FY2021 · AI · contact PI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$714,404
R01 · FY2021 · AI
Biofilm Induced Extracellular Vesicle Pathogenesis$378,741
R01 · FY2021 · AI · contact PI
Admin Core$205,429
U19 · FY2021 · AI · contact PI
Molecular Mycology: Current Approaches to Fungal Pathogenesis (MoMy) Training Course$108,108
R25 · FY2021 · AI
Novel antimicrobials targeting MDR pathogens from animal microbial symbionts$6,020,201
U19 · FY2020 · AI · contact PI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$745,652
R01 · FY2020 · AI
In vivo Core$620,620
U19 · FY2020 · AI · contact PI
Biofilm Induced Extracellular Vesicle Pathogenesis$378,741
R01 · FY2020 · AI · contact PI
Admin Core$205,060
U19 · FY2020 · AI · contact PI
An optogenetic toolkit for spatiotemporal control of gene expression in Candida albicans$191,612
R21 · FY2020 · AI
Novel antimicrobials targeting MDR pathogens from animal microbial symbionts$6,205,014
U19 · FY2019 · AI · contact PI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$757,553
R01 · FY2019 · AI
In vivo Core$622,999
U19 · FY2019 · AI · contact PI
Biofilm Induced Extracellular Vesicle Pathogenesis$378,741
R01 · FY2019 · AI · contact PI
An optogenetic toolkit for spatiotemporal control of gene expression in Candida albicans$235,067
R21 · FY2019 · AI
Admin Core$194,032
U19 · FY2019 · AI · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,097,773
U19 · FY2018 · AI · contact PI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$801,630
R01 · FY2018 · AI
Metabolomics driven discovery of drug leads from symbiotic bacteria$504,183
U19 · FY2018 · AI · contact PI
Mechanism of Action$463,540
U19 · FY2018 · AI · contact PI
Biofilm Induced Extracellular Vesicle Pathogenesis$391,991
R01 · FY2018 · AI · contact PI
In Vivo CORE$335,448
U19 · FY2018 · AI · contact PI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$212,801
U19 · FY2018 · TW · contact PI
Admin-Core-001$140,572
U19 · FY2018 · AI · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,190,133
U19 · FY2017 · AI · contact PI
Mechanism of Action$520,297
U19 · FY2017 · AI · contact PI
Metabolomics driven discovery of drug leads from symbiotic bacteria$474,083
U19 · FY2017 · AI · contact PI
In Vivo CORE$369,870
U19 · FY2017 · AI · contact PI
Function And Genetic Control of Matrix Carbohydrates in Candida Biofilms$353,525
R01 · FY2017 · AI · contact PI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$212,801
U19 · FY2017 · TW · contact PI
Admin-Core-001$140,572
U19 · FY2017 · AI · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,190,133
U19 · FY2016 · AI · contact PI
Mechanism of Action$517,287
U19 · FY2016 · AI · contact PI
Metabolomics driven discovery of drug leads from symbiotic bacteria$475,093
U19 · FY2016 · AI · contact PI
In Vivo CORE$369,870
U19 · FY2016 · AI · contact PI
Function And Genetic Control of Matrix Carbohydrates in Candida Biofilms$353,525
R01 · FY2016 · AI · contact PI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$212,801
U19 · FY2016 · TW · contact PI
Admin Core$143,582
U19 · FY2016 · AI · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,329,683
U19 · FY2015 · AI · contact PI
Mechanism of Action$447,425
U19 · FY2015 · AI · contact PI
In Vivo CORE$390,733
U19 · FY2015 · AI · contact PI
Metabolomics driven discovery of drug leads from symbiotic bacteria$368,824
U19 · FY2015 · AI · contact PI
Function And Genetic Control of Matrix Carbohydrates in Candida Biofilms$353,525
R01 · FY2015 · AI · contact PI
Antibiotic targeting of protein interfaces in bacterial genome maintenance comple$184,085
R21 · FY2015 · AI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$179,816
U19 · FY2015 · TW · contact PI
Admin Core$152,848
U19 · FY2015 · AI · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,433,302
U19 · FY2014 · AI · contact PI
Mechanism of Action$483,712
U19 · FY2014 · AI · contact PI
Metabolomics driven discovery of drug leads from symbiotic bacteria$399,022
U19 · FY2014 · AI · contact PI
In Vivo CORE$386,016
U19 · FY2014 · AI · contact PI
Function And Genetic Control of Matrix Carbohydrates in Candida Biofilms$353,525
R01 · FY2014 · AI · contact PI
Antibiotic targeting of protein interfaces in bacterial genome maintenance comple$221,710
R21 · FY2014 · AI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$139,255
U19 · FY2014 · TW · contact PI
Admin Core$133,847
U19 · FY2014 · AI · contact PI
Function And Genetic Control of Matrix Carbohydrates in Candida Biofilms$344,181
R01 · FY2013 · AI · contact PI
Antifungal Resistance Mechanism in Biofilm Growing candida albicans$360,059
R01 · FY2012 · AI · contact PI
Antifungal Resistance Mechanism in Biofilm Growing candida albicans$360,059
R01 · FY2011 · AI · contact PI
Antifungal Resistance Mechanism in Biofilm Growing candida albicans$363,696
R01 · FY2010 · AI · contact PI
TRAINING IN THE USE OF BRUKER AND VARIAN SPECTROMETERS AND NMR$122
P41 · FY2010 · RR · contact PI
FLUCONAZOLE-BIOFILM MATRIX IN CANDIDA ALBICANS$61
P41 · FY2010 · RR · contact PI
Antifungal Resistance Mechanism in Biofilm Growing candida albicans$367,370
R01 · FY2009 · AI · contact PI
Antifungal Resistance Mechanism in Biofilm Growing candida albicans$367,370
R01 · FY2008 · AI · contact PI
Pharmacodynamics in Antifungal Resistance$129,735
K08 · FY2005 · AI
Pharmacodynamics in Antifungal Resistance$129,735
K08 · FY2004 · AI
Pharmacodynamics in Antifungal Resistance$129,735
K08 · FY2003 · AI
Pharmacodynamics in Antifungal Resistance$118,935
K08 · FY2002 · AI
Pharmacodynamics in Antifungal Resistance$118,935
K08 · FY2001 · AI